ADC Therapeutics SA (ADCT) stock
ADCTNYSEPharmaceutical PreparationsFiscal year ends December 31
$1.34−0.07 (-4.96%)
Close on Nov 13, 2026Market cap $171.08MP/E –Yield –
ADC Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
ADC Therapeutics's gross margin for the twelve months ending Dec 31, 2023 was 96.4%. For fiscal 2025 it was 92.9%, against 91.6% the year before. The highest annual figure on record is 100.0% in fiscal 2019.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 92.9% | +1.3 |
| FY2024 | Dec 31, 2024 | 91.6% | −4.8 |
| FY2023 | Dec 31, 2023 | 96.4% | −2.1 |
| FY2022 | Dec 31, 2022 | 98.4% | +2.5 |
| FY2021 | Dec 31, 2021 | 95.9% | −4.1 |
| FY2019 | Dec 31, 2019 | 100.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | 98.5% | −0.8 |
| Q3 FY2023 | Sep 30, 2023 | 97.5% | −0.8 |
| Q2 FY2023 | Jun 30, 2023 | 93.2% | +6.3 |
| Q1 FY2023 | Mar 31, 2023 | 96.9% | −2.0 |
| Q4 FY2022 | Dec 31, 2022 | 99.3% | +3.8 |
| Q3 FY2022 | Sep 30, 2022 | 98.3% | +2.1 |
| Q2 FY2022 | Jun 30, 2022 | 86.9% | −9.9 |
| Q1 FY2022 | Mar 31, 2022 | 98.9% | – |
| Q4 FY2021 | Dec 31, 2021 | 95.5% | – |
| Q3 FY2021 | Sep 30, 2021 | 96.2% | – |
| Q2 FY2021 | Jun 30, 2021 | 96.8% | – |
See a number that looks wrong?